Literature DB >> 21838584

Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy.

Karsten E Schober1, Taye M Hart, Joshua A Stern, Xiaobai Li, Valerie F Samii, Lisa J Zekas, Brian A Scansen, John D Bonagura.   

Abstract

OBJECTIVE: To evaluate the effects of treatment on respiratory rate, serum natriuretic peptide concentrations, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure (CHF) secondary to degenerative mitral valve disease (MVD) and dilated cardiomyopathy (DCM).
DESIGN: Prospective cohort study. ANIMALS: 63 client-owned dogs. PROCEDURES: Physical examination, thoracic radiography, analysis of natriuretic peptide concentrations, and Doppler echocardiography were performed twice, at baseline (examination 1) and 5 to 14 days later (examination 2). Home monitoring of respiratory rate was performed by the owners between examinations.
RESULTS: In dogs with MVD, resolution of CHF was associated with a decrease in respiratory rate, serum N-terminal probrain natriuretic peptide (NT-proBNP) concentration, and diastolic functional class and an increase of the ratio of peak velocity of early diastolic transmitral flow to peak velocity of early diastolic lateral mitral annulus motion (E:Ea Lat). In dogs with DCM, resolution of CHF was associated with a decrease in respiratory rate and serum NT-proBNP concentration and significant changes in 7 Doppler echocardiographic variables, including a decrease of E:Ea Lat and the ratio of peak velocity of early diastolic transmitral flow to isovolumic relaxation time. Only respiratory rate predicted the presence of CHF at examination 2 with high accuracy. CONCLUSIONS AND CLINICAL RELEVANCE: Resolution of CHF was associated with predictable changes in respiratory rate, serum NT-proBNP concentration, and selected Doppler echocardiographic variables in dogs with DCM and MVD. Home monitoring of respiratory rate was simple and was the most useful in the assessment of successful treatment of CHF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21838584     DOI: 10.2460/javma.239.4.468

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  8 in total

1.  Detection of congestive heart failure by Doppler echocardiography in cats with hypertrophic cardiomyopathy.

Authors:  Michelle N Rohrbaugh; Karsten E Schober; Jaylyn D Rhinehart; John D Bonagura; Amy Habing; Vedat Yildiz
Journal:  J Vet Intern Med       Date:  2020-05-04       Impact factor: 3.333

2.  Pulmonary Vein-to-Pulmonary Artery Ratio is an Echocardiographic Index of Congestive Heart Failure in Dogs with Degenerative Mitral Valve Disease.

Authors:  A-C Merveille; G Bolen; E Krafft; E Roels; S Gomart; A-L Etienne; C Clercx; K Mc Entee
Journal:  J Vet Intern Med       Date:  2015-09-29       Impact factor: 3.333

3.  Relationship of plasma N-terminal pro-brain natriuretic peptide concentrations to heart failure classification and cause of respiratory distress in dogs using a 2nd generation ELISA assay.

Authors:  P R Fox; M A Oyama; M J Hezzell; J E Rush; T P Nguyenba; T C DeFrancesco; L B Lehmkuhl; H B Kellihan; B Bulmer; S G Gordon; S M Cunningham; J MacGregor; R L Stepien; B Lefbom; D Adin; K Lamb
Journal:  J Vet Intern Med       Date:  2014-10-10       Impact factor: 3.333

4.  Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.

Authors:  A Boswood; S G Gordon; J Häggström; G Wess; R L Stepien; M A Oyama; B W Keene; J Bonagura; K A MacDonald; M Patteson; S Smith; P R Fox; K Sanderson; R Woolley; V Szatmári; P Menaut; W M Church; M L O'Sullivan; J-P Jaudon; J-G Kresken; J Rush; K A Barrett; S L Rosenthal; A B Saunders; I Ljungvall; M Deinert; E Bomassi; A H Estrada; M J Fernandez Del Palacio; N S Moise; J A Abbott; Y Fujii; A Spier; M W Luethy; R A Santilli; M Uechi; A Tidholm; C Schummer; P Watson
Journal:  J Vet Intern Med       Date:  2017-12-06       Impact factor: 3.333

5.  Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.

Authors:  Adrian Boswood; Sonya G Gordon; Jens Häggström; Martin Vanselow; Gerhard Wess; Rebecca L Stepien; Mark A Oyama; Bruce W Keene; John Bonagura; Kristin A MacDonald; Mark Patteson; Sarah Smith; Philip R Fox; Karen Sanderson; Richard Woolley; Viktor Szatmári; Pierre Menaut; Whitney M Church; M Lynne O'Sullivan; Jean-Philippe Jaudon; Jan-Gerd Kresken; John Rush; Kirstie A Barrett; Steven L Rosenthal; Ashley B Saunders; Ingrid Ljungvall; Michael Deinert; Eric Bomassi; Amara H Estrada; Maria J Fernandez Del Palacio; N Sydney Moise; Jonathan A Abbott; Yoko Fujii; Alan Spier; Michael W Luethy; Roberto A Santilli; Masami Uechi; Anna Tidholm; Christoph Schummer; Philip Watson
Journal:  J Vet Intern Med       Date:  2020-03-22       Impact factor: 3.333

6.  Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom.

Authors:  M J Mattin; A Boswood; D B Church; D C Brodbelt
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

7.  Utility of point-of-care lung ultrasound for monitoring cardiogenic pulmonary edema in dogs.

Authors:  Shane D Murphy; Jessica L Ward; Austin K Viall; Melissa A Tropf; Rebecca L Walton; Jennifer L Fowler; Wendy A Ware; Teresa C DeFrancesco
Journal:  J Vet Intern Med       Date:  2020-12-03       Impact factor: 3.175

Review 8.  Management of Chronic Congestive Heart Failure Caused by Myxomatous Mitral Valve Disease in Dogs: A Narrative Review from 1970 to 2020.

Authors:  Mara Bagardi; Viola Zamboni; Chiara Locatelli; Alberto Galizzi; Sara Ghilardi; Paola G Brambilla
Journal:  Animals (Basel)       Date:  2022-01-16       Impact factor: 2.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.